Hypothetical vaccines Archives - Page 2 of 4

Hypothetical vaccines, M72/AS01e

To aid in prioritizing the development of tuberculosis (TB) vaccines most likely to reach the 2050 TB elimination goal, we estimated the impact and cost-effectiveness of a range of vaccine profiles in low- and middle-income countries.

Estimating the epidemiologic impact of new TB vaccines in high-burden settings

2022-2027

This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.

Estimating the epidemiologic impact of new TB vaccines in the U.S.

2022-2024

This is a study funded by the American Lung Association which will explore the potential impact of targeted implementation of a prevention of disease vaccine in a low TB burden country, the U.S.A.

Formative work to understand factors affecting future TB vaccines acceptance and readiness

2023-2027

This project aims to collect data to: 1) Assess health facility and health systems readiness for a new TB vaccine, and 2) Explore decision-making factors for new TB vaccine demand and acceptance

Impact TB vaccination for PLHIV

2023

Modelling to inform PPCs for TB VX for PLHIV

Demand insights for uptake of TB vaccine

2022

Summarize the major swing factors that would determine countries’ preference and effectively drive the uptake of a TB vaccine in terms of the date of introduction and the scale of catch-up campaign to reach the steady state

TB case-finding in the context of future vaccines

2024-2027

Planned

Scenarios for future TB vaccines’ characteristics within which the value and cost-effectiveness of present-day interventions can be explored

Is neglect of self-clearance biasing TB vaccine impact estimates?

2023

exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India

Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio.

2023

BCG revaccination, Hypothetical vaccines, M72/AS01e

From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

2024